They get a type of lung cancer that's often called an adenocarcinoma.

他们得是通常被称为腺癌肺癌。

So, adenocarcinoma arises from columnar glandular epithelium.

腺癌来源于柱状上皮腺体细胞。

However, if the cells look abnormal, that's called dysplasia, and there's a higher risk of developing adenocarcinoma.

然而，如果这些细胞看起来异常，那就叫做异型增生，并且发生腺癌风险更高。

Barrett's esophagus poses a higher risk of developing esophageal adenocarcinoma.

Barrett食患者发生食腺癌风险较高。

The strongest risk factor for adenocarcinoma, on the other hand, is chronic GERD and Barrett's esophagus.

另方面，腺癌最强危险因素是慢性胃食反流病与Barrett食。

On the other hand, adenocarcinoma is the most common type of esophageal cancer in the United States of America, and it originates in the columnar glandular epithelium, most often in the lower third of the esophagus.

另方面，腺癌是在美国最常见食癌类型；腺癌起源于柱状腺上皮细胞，最常位于食下三分之。

Obesity and being a genetically male individual also increase the risk of adenocarcinoma.

肥胖与性别为男性，也会增加罹患腺癌风险。

This is called Barrett's esophagus - or Barrett's metaplasia, and the cylindrical epithelium has a greater risk of degenerating into a particular type of esophageal cancer, called adenocarcinoma.

这被称为Barrett食或Barrett化生，而柱状上皮有更大风险退化为特殊类型食癌，称为腺癌。

Most frequently, adenocarcinoma develops as a consequence of gastroesophageal reflux disease, or GERD for short.

最常见情况是胃食反流（简称GERD）导致食腺癌。

Incidence of NRG1 fusion in patients with cancer is less than 1% However, in lung IMAs (up to 10% of all lung adenocarcinomas), the incidence of NRG1 fusion is 10-30%.

癌症患者中 NRG1 融合发生率低于 1%，然而，在肺 IMA（占所有肺腺癌 10%）中，NRG1 融合发生率为 10-30%。

I remember reading a meta-analysis of the effect of smoking on the risk of adenocarcinoma, right?

我记得读过篇关于吸烟对腺癌风险影响荟萃分析，对吗？

Not by much, and it wasn't statistically significant, but I could say, hey, look, I could cite these two studies, PMID, you know, they showed no increased risk of adenocarcinoma and actually might be slightly protective.

差别不大，而且在统计学上也不显著，但我可以说， 嘿，看，我可以引用这两项研究，PMID，你知道，它们显示腺癌风险没有增加， 实际上可能略有保护作用。

The most frequently reported NRG1 fusion is CD74-NRG1 which most commonly occurs in patients with invasive mucinous adenocarcinomas (IMAs) of the lung, although several other NRG1 fusion partners have been identified in patients with lung cancer.

最常报道 NRG1 融合是 CD74-NRG1，最常发生在肺部侵袭性粘液腺癌 (IMA) 患者中，尽在肺癌患者中还发现了其他几 NRG1 融合伙伴。

And I think the overall effect was like three or 400% increased risk of adenocarcinoma.

我认为总体影响是腺癌风险增加 300％ 或 400％。

The FDA has approved capmatinib in this subset of lung adenocarcinomas.

FDA 已批准卡马替尼用于治疗这肺腺癌。

Patients with adenocarcinoma should have genomic testing for EGFR, ALK, ROS1, KRAS, NTRK, BRAF, RET, MET, HER2 (ERBB2) and NRG1 at diagnosis.

腺癌患者在诊断时应进行 EGFR、ALK、ROS1、KRAS、NTRK、BRAF、RET、MET、HER2 (ERBB2) 和 NRG1 基因组检测。

Well-differentiated tumors with adenocarcinoma or squamous cell carcinoma morphology can be diagnosed by routine light microscopy, without the need for IHC.

具有腺癌或鳞状细胞癌形态分化良好肿瘤可以通过常规光学显微镜进行诊断，而不需要 IHC。

BRAF mutations BRAF mutations are observed in 1-2% of lung adenocarcinomas.

BRAF 突变 1-2% 肺腺癌中观察到 BRAF 突变。

Non-small-cell lung cancer (NSCLC), which includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma, accounts for 80- 85% of all lung cancers.

非小细胞肺癌（NSCLC）包括腺癌、鳞状细胞癌和大细胞癌，占所有肺癌80-85%。

Guidelines recommend genomic profiling for all patients with advanced non-squamous NSCLC (including adenocarcinoma, large cell carcinoma and NSCLC NOS) and it should also be considered for patients with advanced squamous cell carcinoma.

指南建议对所有晚期非鳞状细胞癌（包括腺癌、大细胞癌和 NSCLC NOS）患者进行基因组分析，晚期鳞状细胞癌患者也应考虑进行基因组分析。